Amsacrine (amsa) is a topoisomerase II inhibitor used in oncology as a chemotherapeutic agent, primarily for the treatment of acute leukemias (particularly acute myeloid leukemia, AML). It works by intercalating DNA and stabilizing the topoisomerase II-DNA complex, leading to DNA breaks and apoptosis.
Key Points for Oncology Pharmacists:
- Indications: Relapsed/refractory AML (less commonly ALL).
- Administration: IV infusion (typically over 60–90 minutes).
- Toxicities: Myelosuppression (dose-limiting), cardiotoxicity (QT prolongation, arrhythmias), hepatotoxicity, mucositis.
- Monitoring: ECG (QT interval), LFTs, CBC, electrolytes (K⁺/Mg²⁺).
- Drug Interactions: CYP3A4 substrates/inhibitors (metabolized via liver).
Amsacrine is rarely used today due to newer agents but remains an option in certain protocols.
Would you like details on dosing or specific protocols?